Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Scientists Unwind More Mysteries of the Cellular Clock

By LabMedica International staff writers
Posted on 08 Dec 2014
A new study surveying circadian gene expression provides a new understanding of how one clock leads to at least 8 different subclocks, and may suggest a new venue for drug treatment of clock-based metabolic disorders.

Human existence is basically circadian in that most people wake in the morning, sleep in the evening, and eat in between. More...
Body temperature, metabolism, and hormone levels all fluctuate throughout the day and disruption of those cycles can lead to disorders and diseases. The wheels and springs of the molecular clock underlying these circadian rhythms include transcription factors (TFs) that control oscillation of expression of circadian genes.

Not all circadian cycles peak at the same time – some peak in the morning, others in the evening, etc. The question is how does a single clock keep time in multiple phases at once? 

New findings come from the team of Mitchell Lazar, MD, PhD, and professor at the University of Pennsylvania’s Perelman School of Medicine (Philadelphia, PA, USA) in a report of a genome-wide survey of circadian protein-coding genes and gene-expression enhancers, parts of the “dark matter” of the genome in that they don’t encode for proteins. The team took advantage of new tools based on high-density DNA sequencing to measure the activity of enhancers throughout the day in the livers of mice. They found that many enhancers, like circadian genes themselves, have a daily oscillation that is in phase with nearby genes – both the enhancer and gene activity peak at the same time each day. The activities of the enhancers themselves are, in turn, governed by distinct TFs.

Grouping the enhancers into 8, 3-hour phases based on when they peak, the team asked which TFs are capable of binding to the enhancers in each set. Remarkably, the team found that enhancers that are in the same phase tend to be bound by the same TFs. For instance, one circadian component, CLOCK, binds enhancers that are most active during one particular 3-hour period. Another protein, Rev-erba, binds 12 hours later. Loss of any one of the TFs dysregulates a subset of oscillating genes while leaving genes tuned to other circadian phases unaffected.

“Different transcription factors control different phases,” said Lazar, “That explains how one clock leads to at least 8 different subclocks.”

Also important is that genes that oscillate with the same phase tend to have related functions, which are distinct from the pathways controlled at other times. Genes involved in insulin signaling peak at a different time than genes that control sugar metabolism, for instance.

Lazar suggests it might be possible to tweak pharmaceutical regimens to make them more efficient by delivering drugs only when the pathways they impact are actually active – a strategy that could minimize unintended side effects. Toward “a proof-of-concept for a new principle of drug treatment for metabolic disorders,” he said, “this is a real step in that direction.”

The study, by Fang B, Everett L, Jager J, et al., was published in the journal Cell, online ahead of print November 20, 2014.

Related Links:

Perelman School of Medicine at the University of Pennsylvania
University of Pennsylvania Health System 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.